Comparative Pharmacology
Head-to-head clinical analysis: CHEWTADZY versus FINASTERIDE AND TADALAFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHEWTADZY versus FINASTERIDE AND TADALAFIL.
CHEWTADZY vs FINASTERIDE AND TADALAFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Finasteride is a 5α-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that enhances nitric oxide-mediated vasodilation by increasing cyclic guanosine monophosphate (cGMP) in smooth muscle.
2 mg orally twice daily
One capsule containing finasteride 5 mg and tadalafil 5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (CrCl <30 mL/min)
Finasteride: 6-8 hours (elderly ~8 hours); Tadalafil: 17.5 hours (enables once-daily dosing).
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Finasteride: 57% feces, 39% urine (metabolites); Tadalafil: 36% urine, 61% feces (mostly metabolites).
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor